Treatment with paxalisib (formerly GDC-0084), an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival (OS) signal in patients with glioblastoma, according to interim data from an ongoing phase II study.
These findings had been scheduled for live presentation at the 2020 AACR Annual Meeting, which was scheduled to take place in San Diego, from April 24 to 29; however, the live meeting was cancelled due to the COVID-19 crisis. Thus, Kazia decided to report these data now.
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study. Published April 7, 2020. https://yhoo.it/2JP8QOA. Accessed April 7, 2020.
... to read the full story